News Alnylam halts trials of haemophilia drug after patient death Trials will resume once safety protocols have been reviewed.
News NICE wants to axe funding for two thyroid cancer drugs NICE unconvinced by survival data from Ipsen and Sanofi drugs
News Novo Nordisk may drop US insulin price as Sanofi suffers Biosimilar Lantus is causing rivals to cut prices to compete
News Ablynx and Sanofi sign potential 2.4bn euro R&D deal Collaboration will develop drugs for inflammatory diseases
News Amicus to file Fabry drug after FDA changes mind Regulator drops demand for further phase 3 trial.
News Sanofi $750m acquisition gives it edge in flu vacccine marke... Biotech's Flublok is only FDA-approved cell-based flu jab
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
